PRZOOM - /newswire/ -
Hoboken, NJ, United States, 2013/03/04 - John Wiley & Sons, Inc. announced the launch of a new open access, interdisciplinary journal providing rapid publication of cutting-edge research across the broad field of immunology (NYSE: JWa, JWb) - ImmunityInflammationDisease.com / WileyOpenAccess.com. NYSE: JWa, JWb
Immunity, Inflammation and Disease, the latest journal to be launched from the Wiley Open Access program, is supported by a number of major societies; British Society for Immunology; European Federation of Immunological Societies; European Academy of Allergy and Clinical Immunology; and the British Society for Allergy and Clinical Immunology, as well as leading journals in the field, including Allergy (Impact Factor 6.3), European Journal of Immunology (Impact Factor 5.1) and Clinical and Experimental Allergy (Impact Factor 5.0).
All articles in Immunity, Inflammation and Disease will be published open access under the Creative Commons Attribution (CC-BY) License on Wiley Online Library and deposited in PubMed Central immediately upon publication. A publication fee will be payable by authors on acceptance of their articles. Authors affiliated with, or funded by, an organization that has a Wiley Open Access Account can publish without directly paying any publication charges.
Marc Veldhoen, a group leader at the Babraham Institute in Cambridgeshire, UK, has been appointed as Editor-in-Chief for the new journal. Dr. Veldhoen studied Medical Biology at the Faculty of Medicine, Utrecht University, The Netherlands and went on to pursue his post doctorate at the National Institute for Medical Research Mill Hill, UK.
“It is my hope and goal with Immunity, Inflammation and Disease to make a contribution towards quality open access scientific publishing and to stimulate debate. Being part of Wiley means we will make full use of its experience with quality peer reviewed scientific publishing,” said Dr. Veldhoen. “My aims are to shape it into a high quality journal publishing new and original data, and to encourage the preservation of the original scientific method of open discussion and frank exchange of thoughts and ideas.”
“We are delighted to be launching this new open access journal in immunology, particularly with support of our long term publishing partners which will be invaluable in ensuring that the new journal goes from strength to strength,” said Bob Campbell, Senior Publisher, Wiley.
The journal is open to submissions now. Visit the journal’s website immunityinflammationdisease.com for further information and future updates.
About Wiley Open Access
Wiley Open Access (wileyopenaccess.com) is an initiative from Wiley to drive quality peer reviewed publishing with speed and efficiency through open access publication. All research articles published in Wiley Open Access journals are immediately freely available to read, download and share. The fully open access journals are published in collaboration with authoritative journals and societies as well as supported by internationally renowned editorial board members.
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (wiley.com), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia.